Aim: To compare the efficacy and safety of once-weekly dulaglutide with that of insulin glargine in combination with metformin and/or a sulphonylurea in mainly Asian patients with type 2 diabetes mellitus (T2DM).
| INTRODUCTION
Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes, 1 and is a progressive disease characterized by a combination of varying degrees of insulin resistance and relative insulin secretory deficiency. 2 Generally, patients with T2DM inadequately controlled on lifestyle measures and oral antihyperglycaemic medication (OAM) need further injectable therapy to attain optimal glycaemic control. 3, 4 Once-daily basal insulin is a frequent option to maintain glycaemic control, but is associated with adverse effects such as hypoglycaemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists stimulate insulin secretion in a glucose-dependent manner and inhibit the release of glucagon, and evidence shows that they improve glucose control and are also associated with weight loss and lower risk of hypoglycaemia. [5] [6] [7] [8] [9] [10] Dulaglutide is an approved long-acting human GLP-1 receptor agonist, administered as a once-weekly subcutaneous injection for the treatment of T2DM. 11, 12 Dulaglutide has been evaluated in several phase III trials known as the global AWARD (Assessment of Weekly AdministRation of LY2189265 [dulaglutide] in Diabetes) programme in mainly white and Hispanic/Latino patients with T2DM, showing that dulaglutide as monotherapy or in combination with other antidiabetic medication was effective, generally safe and well tolerated. 8, [13] [14] [15] [16] [17] [18] In AWARD-2, once-weekly dulaglutide 1.5 mg demonstrated greater glycated haemoglobin (HbA1c) reduction and weight loss compared with daily insulin glargine in patients with T2DM treated with maximum tolerated doses of metformin and glimepiride. The safety profile showed a higher incidence of gastrointestinal adverse events (AEs) and a lower risk of hypoglycaemia compared with glargine without forced titration 8 ; however, limited data exist comparing dulaglutide 1.5 mg with glargine in Asian patients with T2DM. 19 The objective of the present study was to compare the efficacy and safety of once-weekly dulaglutide with daily insulin glargine in mainly Asian patients with T2DM who were inadequately controlled on treatment with metformin and/or a sulphonylurea.
| PATIENTS AND METHODS

| Study design and patients
This 52-week, randomized, parallel-arm, open-label (blinded to dulaglutide dose), active comparator non-inferiority study consisted of three periods: a screening (2 weeks) and lead-in period (2 weeks); a treatment period (52 weeks); and a safety follow-up period (30 days; Figure 1A ). The study was conducted at 45 sites in China, Russia, Mexico and South Korea.
Patients aged ≥18 years with a diagnosis of T2DM for at least 6 months, a body mass index ≥19.0 and ≤35.0 kg/m 2 and HbA1c
≥53.0 mmol/mol (7.0%; considered inadequate glycaemic control) and ≤96.7 mmol/mol (11.0%), who had been taking metformin and/or a sulphonylurea for at least 3 months and were on a stable therapeutic dose (at least half the maximum dose according to the product information in the country of treatment) for at least 8 weeks before screening, were eligible. Patients were excluded from the study if they had type 1 diabetes, had a clinically significant gastric emptying abnormality, had a history of pancreatitis, had a serum calcitonin concentration ≥20 ng/L (or 5.83 pmol/L), were taking insulin treatment or had been treated with a GLP-1 receptor agonist within 3 months before screening.
Institutional review boards provided written approval of the protocol, and patients provided written informed consent before any study-related activities. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practices. 20 The trial is registered with ClinicalTrials.gov (NCT01648582).
| Randomization and masking
Eligible patients were randomized (1:1:1) to subcutaneously injected once-weekly dulaglutide 1.5 mg or dulaglutide 0.75 mg, or once-daily insulin glargine according to a computer-generated random sequence using an interactive voice-response system. Randomization was stratified by country, baseline HbA1c concentration (<8.5% or ≥8.5%, 69.4 mmol/mol) and type of baseline OAM regimen.
| Procedures
During the study treatment period, patients in the two dulaglutide treatment groups received a fixed, double-blind dose of dulaglutide (either 1.5 or 0.75 mg) once weekly as a subcutaneous injection. This study used an insulin glargine dosing algorithm that has previously been found to be safe and effective in Japanese patients in conjunction with glimepiride. 21 Patients in the glargine group started their oncedaily subcutaneous injection before bedtime on the day of randomiza- 
| Statistical analyses
The study was designed with 90% power to show non-inferiority of dulaglutide 1.5 mg versus glargine for change from baseline in HbA1c at the 26-week primary endpoint, assuming a non-inferiority margin of 0.4%, no true difference in HbA1c reduction between dulaglutide 1.5 mg and glargine, an SD of 1.3%, and a one-sided α-value of 0.025.
This corresponds to a randomized 263 patients per treatment group, with an assumed drop-out rate of 15%. Tree-gatekeeping was used to control the family-wise type 1 error rate at 0.025 (one-sided) while assessing non-inferiority/superiority of dulaglutide 1.5 mg versus No explicit imputation of missing post-baseline HbA1c data was performed, as the MMRM implicitly adjusts for them. Percentage calculations included only patients with available data in the denominator, unless otherwise specified. Type 1 error was controlled for primary and gated secondary objectives. As per convention, a P value <0.05 was taken to indicate statistical significance, but should mostly be interpreted as descriptive. All adjusted means refer to least squares (LS) means. All analyses were performed in SAS version 9.3.
| RESULTS
A total of 774 patients were randomly assigned to one of the three treatment groups. Six patients in the glargine group did not take the study drug (five patients decided to discontinue treatment and one patient did not meet the inclusion criteria). A total of 709 patients completed the 26-week study period and 672 patients completed the study up to week 52. The number of patients who discontinued the study was similar across groups, and the most common reason for discontinuation was patient decision ( Figure 1B ). The baseline demographic and clinical characteristics of the 755 patients in the mITT population were similar among treatment groups (Table 1) . In all the groups, most patients were Asian (83.6%). During the study treatment, 
| Efficacy
The LS mean (SE) changes from baseline in HbA1c at the 26-week primary endpoint were −18.9 (0.73) mmol/mol (−1.73 [0.067]%) for Figure 2B shows HbA1c values over time up to week 52 (Table S2) . were demonstrated at week 52 ( Figure 2F ).
| Safety
For overall safety, there was a higher incidence of treatmentemergent AEs during 52 weeks in both dulaglutide doses than in glargine, primarily because of a higher incidence of gastrointestinal AEs.
Gastrointestinal AEs, including diarrhoea and nausea, were the most frequently reported AEs for patients taking dulaglutide ( During the first 26 weeks, the incidence of total hypoglycaemia was lower for dulaglutide 1.5 mg and dulaglutide 0.75 mg than for glargine. The rate of total hypoglycaemia was also reported in patients with dulaglutide 1.5 mg and dulaglutide 0.75 mg (1.27 and 0.98 events/patient/year, respectively), and those receiving glargine (2.13 events/patient/year). For the patients taking sulphonylureas (with or without metformin) up to 26 weeks, the rate of hypoglycaemia was 1.59, 1.61 and 3.34 events/patient/year for dulaglutide 1.5 mg, dulaglutide 0.75 mg and glargine, respectively. It was higher for glargine compared with dulaglutide 1.5 mg (P = 0.007) or dulaglutide 0.75 mg (P = 0.008). The incidence and rate of nocturnal hypoglycaemia were significantly lower with dulaglutide versus glargine at week 52.
( Table 2, Tables S2 and S3 , Supporting Information.) No events of severe hypoglycaemia were reported during the study period.
Mean increases in pancreatic enzymes from baseline to week 52 were greater in the dulaglutide groups than in the glargine group.
The incidence of clinically relevant increases in lipase (≥3 × upper limit of normal) was numerically higher with dulaglutide 1.5 mg (n = 4) and 0.75 mg (n = 4) than with glargine (n = 0). No patients had values of ≥3 × upper limit of normal for total or pancreatic amylase during the study (Table 2) . No pancreatitis events were confirmed upon adjudication. No cases of pancreatic cancer were reported during the study.
In the dulaglutide groups, 21 patients (4.1%) developed treatment-emergent dulaglutide anti-drug antibodies (Table 2) , and one patient in the dulaglutide 0.75 mg group experienced mild injection site reaction. Severe hypoglycaemia, n (%) studies, the present study seemed to include higher mean PPG and greater PPG excursions at baseline ( Figure 2E ) compared with the AWARD-2 study. 
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At week 26 and week 52, the pre-morning blood glucose values obtained from seven-point SMBG profiles showed significant and clinically meaningful reductions in both the dulaglutide groups and the glargine group. Reductions with glargine were significantly greater than with both dulaglutide doses, while the decreases in pre-midday and pre-evening meal among the three arms were generally similar.
With regard to PPG changes, both dulaglutide 1.5 mg and dulaglutide 0.75 mg had a greater effect than glargine. Notably, dulaglutide 1.5 mg achieved significantly greater reductions than glargine at all three 2-hour PPG assessments at week 26 and week 52 (Table S4, Supporting Information). Based on the dual effects on fasting glucose and PPG, greater reductions in postprandial excursions were observed in both dulaglutide doses compared with glargine, especially in morning 2-hour excursion and midday 2-hour excursion (Table S5 , Supporting Information). In comparison with the AWARD-2 study, the present study showed greater improvements in PPG and PPG excursion; this may have been attributable to the higher baseline PPG in Asian patients and multiple mechanisms of dulaglutide to improve PPG levels, including effect on glucose-dependent first-and second-phase insulin secretion, delay in gastric emptying and decreasing appetite. class. 16, 30, 31 An increase in pulse rate was observed with dulaglutide and was similar to changes observed within the GLP-1 receptor agonist class. 8, [13] [14] [15] [16] [17] [18] In the present study, dulaglutide treatment was associated with a low incidence (4.1%) of treatment-emergent dulaglutide anti-drug antibodies. This is consistent with the pooled data from nine phase II and phase III dulaglutide trials. 32 The main limitation of the present study was its open-label design, which could have affected physicians, and patients' behaviour;
however, using a double-blind design would have been difficult because glargine requires titration throughout the study period. It is possible that a more stringent titration of glargine achieving a lower mean FPG would have led to a greater decrease in HbA1c than that observed. Nevertheless, the data may actually reflect the most likely concerns in clinical practice when making decisions on insulin titration, such as the fear of hypoglycaemia and weight gain, especially in the absence of forced titration. In conclusion, in mainly Asian patients with T2DM who fail to achieve optimal glycaemic control on metformin and/or a sulphonylurea, treatment with once-weekly dulaglutide 0.75 or 1.5 mg, simultaneously addressing both fasting glucose and PPG, resulted in clinically meaningful improvement in glycaemic control associated with moderate body weight loss and a lower risk of hypoglycaemia compared with glargine.
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